Expert Seeks to Assess Opioid Access Disparities in Younger Cancer Population


After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.

Assessing disparities in opioid access among younger patients with cancer and those who have different insurance types, such as Medicaid or commercial insurance, should be a future area of focus, according to Andrea C. Enzinger, MD.

In an interview with CancerNetwork®, Enzinger, an assistant professor of medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute, discussed how these areas of focus will work to build on a study investigating racial and ethnic disparities in opioid access for patients with cancer near the end of life. In particular, she emphasized that the degree of disparities observed in the study are likely quite larger than the data indicated, as it primarily included older patients.

In addition to investigating disparities in younger populations, Enzinger indicated that future research should also explore systems and mechanisms that may perpetuate inequal access to opioids across different communities. She suggested that follow-up studies will clarify whether factors such as poverty or rurality impacted a patient’s likelihood of having access to opioids.


Our team is planning a number of follow-up studies; there are some important unanswered questions. This is the largest study to date to look at the magnitude and the scope of opioid access disparities in cancer populations. But we’re just looking at older populations with terminal cancer, and it’s important to highlight that the degree of disparities we see here are probably much larger if you look at younger populations or if you look at those with mixed-insurance types.

We are really interested in looking at disparities in younger populations and those who may have Medicaid or commercial insurance. We’re also interested in looking at different phases of cancer care, for example, during definitive cancer treatment or after surgery.

It’s really important to know where the disparities are the worst. The other thing that our team is really interested in looking at is mechanisms and why this is happening. We tried to look at a few possible mechanisms by running models that adjusted for the characteristics of patients and communities where they lived, as well as how deprived the communities were.

We are wondering if this was all due to structural factors. Adjusting for that, for poverty, and for whether patients lived in urban or rural communities really made no difference on the magnitude of the disparities that we saw.


Enzinger AC, Ghosh K, Keating NL, et al. Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol. Published online January 10, 2023. doi:10.1200/JCO.22.01413

Related Videos
Prophylactic cranial irradiation may not be worthwhile for treating patients with extensive-stage small cell lung cancer based on conflicting data, according to Gregory Peter Kalemkerian, MD.
FDA-approved immunotherapy options such as atezolizumab and durvalumab have produced substantial benefits in certain groups of patients with extensive-stage small cell lung cancer, says Gregory Peter Kalemkerian, MD.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.